
Expert
Michael Owens, Ph.D.
Director of the Center for Alcohol & Drug Abuse Studies
Dr. Owens is the Director of the Center for Alcohol and Drug Abuse Studies, and a Professor of Pharmacology and Toxicology in the College of Medicine at the University for Arkansas for Medical Sciences (UAMS) in Little Rock, Arkansas. His research interests are antibody-based medications, experimental therapeutics, and drug abuse.
Dr. Owens is a founder and Chief Scientific Officer of InterveXion Therapeutic LLC, a pharmaceutical company based on Dr. Owens’ monoclonal antibody and vaccine medications. In recognition of his research and academic accomplishments at UAMS, he was awarded a Wilbur D. Mills Endowed Chair in Alcohol and Drug Abuse Prevention in 2000.
“Research in my laboratory involves experimental therapeutics and preclinical development of antibody-based medications for the treatment of drug abuse. Our first medication, an anti-methamphetamine monoclonal antibody, is currently in an FDA approved clinical trials.”
